Triple levofloxacin-based rescue therapy is an accepted empirical third-line treatment

Am J Gastroenterol. 2006 Aug;101(8):1938; author reply 1938-9. doi: 10.1111/j.1572-0241.2006.00684_1.x.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Amoxicillin / adverse effects
  • Amoxicillin / therapeutic use
  • Ampicillin / adverse effects
  • Ampicillin / therapeutic use
  • Antacids / adverse effects
  • Antacids / therapeutic use
  • Anti-Bacterial Agents / adverse effects
  • Anti-Bacterial Agents / therapeutic use
  • Bismuth / adverse effects
  • Bismuth / therapeutic use
  • Breath Tests
  • Clarithromycin / adverse effects
  • Clarithromycin / therapeutic use
  • Drug Therapy, Combination
  • Enzyme Inhibitors / adverse effects
  • Enzyme Inhibitors / therapeutic use
  • Helicobacter Infections / drug therapy*
  • Helicobacter pylori* / drug effects
  • Helicobacter pylori* / isolation & purification
  • Humans
  • Levofloxacin
  • Metronidazole / adverse effects
  • Metronidazole / therapeutic use
  • Ofloxacin / adverse effects
  • Ofloxacin / therapeutic use
  • Omeprazole / adverse effects
  • Omeprazole / therapeutic use
  • Protein Synthesis Inhibitors / adverse effects
  • Protein Synthesis Inhibitors / therapeutic use
  • Tetracycline / adverse effects
  • Tetracycline / therapeutic use
  • Treatment Failure

Substances

  • Antacids
  • Anti-Bacterial Agents
  • Enzyme Inhibitors
  • Protein Synthesis Inhibitors
  • Metronidazole
  • Levofloxacin
  • Ampicillin
  • Amoxicillin
  • Ofloxacin
  • Tetracycline
  • Clarithromycin
  • Omeprazole
  • Bismuth